Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 3/20 | 0.42 |
| ▸ | IL6ST | P40189 | 1/20 | 0.40 |
| ▸ | IDH1 | O75874 | 8/20 | 0.40 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.35 |
| ▸ | LTB4R | Q15722 | 2/20 | 0.34 |
| ▸ | LTB4R2 | Q9NPC1 | 2/20 | 0.34 |
| ▸ | SLC6A9 | P48067 | 2/20 | 0.34 |
| ▸ | NAAA | Q02083 | 2/20 | 0.34 |
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
| ▸ | MMP2 | P08253 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3753534 | 0.87 | IL6ST (0.45) | PPARAIL6STIDH1AGTR2LTB4R | |
| SCHEMBL3753536 | 0.87 | IL6ST (0.45) | PPARAIL6STIDH1AGTR2LTB4R | |
| SCHEMBL16294896 | 0.86 | PPARA (0.46) | PPARAIL6STIDH1AGTR2LTB4R | |
| SCHEMBL16307092 | 0.86 | PPARA (0.46) | PPARAIL6STIDH1AGTR2LTB4R | |
| SCHEMBL17700747 | 0.86 | PPARA (0.46) | PPARAIL6STIDH1AGTR2LTB4R | |
| SCHEMBL2754727 | 0.85 | PPARA (0.42) | PPARAIL6STIDH1AGTR2LTB4R | |
| SCHEMBL613403 | 0.85 | PPARA (0.42) | PPARAIL6STIDH1AGTR2LTB4R | |
| SCHEMBL613402 | 0.85 | PPARA (0.42) | PPARAIL6STIDH1AGTR2LTB4R | |
| SCHEMBL24418522 | 0.78 | IL6ST (0.52) | PPARAIL6STIDH1AGTR2NAAA | |
| SCHEMBL9554132 | 0.78 | PPARA (0.48) | PPARAIL6STIDH1AGTR2NAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8076516-B2 | Amine derivative compounds for treating ophthalmic diseases and disorders | ACUCELA, INC. (US) | 2011-12-13 | — | — | US | disclosed |
| US-8076516-B2 | Amine derivative compounds for treating ophthalmic diseases and disorders | ACUCELA, INC. (US) | 2011-12-13 | — | — | US | disclosed |
| US-20090281149-A1 | Amine Derivative Compounds for Treating Ophthalmic Diseases and Disorders | ACUCELA, INC. (US) | 2009-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281149-A1 | Amine Derivative Compounds for Treating Ophthalmic Diseases and Disorders | PDE6D, CLN6, AADAT | PPARA 2018/4885IL6ST 4269/4885IDH1 3982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.